Chronic Myelogenous Leukemia
Mostrando 1-12 de 166 artigos, teses e dissertações.
-
1. Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic
ABSTRACT The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay.
Hematol., Transfus. Cell Ther.. Publicado em: 2020-09
-
2. Hott M. Luto: Trato & Retrato
ABSTRACT The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay.
Saúde debate. Publicado em: 2020-09
-
3. Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
ABSTRACT Introduction and objective: In this study, we evaluated the influence of the transcript type on hematological and clinical parameters, as well as the event-free survival of 50 patients in the Chronic myeloid leukemia chronic phase. Methods: We reviewed the medical records of 55 patients with Chronic myeloid leukemia. The eligibility criteria were
Hematol., Transfus. Cell Ther.. Publicado em: 10/06/2019
-
4. Hemolytic, anticancer and antigiardial activity of Palythoa caribaeorum venom
Abstract Background Cnidarian venoms and extracts have shown a broad variety of biological activities including cytotoxic, antibacterial and antitumoral effects. Most of these studied extracts were obtained from sea anemones or jellyfish. The present study aimed to determine the toxic activity and assess the antitumor and antiparasitic potential of Palythoa
J. Venom. Anim. Toxins incl. Trop. Dis. Publicado em: 24/05/2018
-
5. Clinical and pathological features of myeloid leukemia cutis
Abstract: Background: Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia. Objective: The purpose of this study was to study the clinical, histopathological and immunohistochemical features of myeloid leukemia cutis. Methods: This was a retrospective study of clinical and pathological features of 10 patients wit
An. Bras. Dermatol.. Publicado em: 2018-03
-
6. Pathologic rupture of the spleen in a patient with acute myelogenous leukemia and leukostasis
Rupture of the spleen can be classified as spontaneous, traumatic, or pathologic. Pathologic rupture has been reported in infectious diseases such as infectious mononucleosis, and hematologic malignancies such as acute and chronic leukemias. Splenomegaly is considered the most relevant factor that predisposes to splenic rupture. A 66-year-old man with acute
Rev. Bras. Hematol. Hemoter.. Publicado em: 2014-07
-
7. Pericardial effusion and cardiac tamponade: clinical manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
The authors report a case with pericardial effusion and cardiac tamponade as a rare clinical manifestation of chronic graft-versus-host disease in a young man with acute myelogenous leukemia submitted to an allogeneic hematopoietic stem cell transplantation from a related donor.
Rev. Bras. Hematol. Hemoter.. Publicado em: 2014-04
-
8. Estudo do metabolismo de microRNAs na resistência de células leucêmicas / Study of microRNA metabolism in leukemik cells resistance
Drug resistance is one of the main obstacles in cancer therapy. Frequently, the treatment of chronic myelogenous leukemia (CML) becomes inefficient due to the emergence of a resistant population of cancer cells. Therefore, comparative studies of resistant and non-resistant CML cell lines is extremely important to the understanding of molecular mechanisms inv
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 11/07/2011
-
9. Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
Chronic myeloproliferative neoplasms arise from clonal proliferation of hematopoietic stem cells. According to the World Health Organization myeloproliferative neoplasms are classified as: chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia, hypereosin
Revista Brasileira de Hematologia e Hemoterapia. Publicado em: 2011
-
10. Relationship of an hRAD54 gene polymorphism (2290 C/T) in an Ecuadorian population with chronic myelogenous leukemia
The hRAD54 gene is a key member of the RAD52 epistasis group involved in repair of double-strand breaks (DSB) by homologous recombination (HR). Thus, alterations of the normal function of these genes could generate genetic instability, shifting the normal process of the cell cycle, leading the cells to develop into cancer. In this work we analyzed exon 18 of
Genetics and Molecular Biology. Publicado em: 12/11/2010
-
11. Molecular monitoring of patients with chronic myeloid leukemia treated with imatinib mesylate and evaluation of treatment resistance mechanisms: mutation of BCR-ABL and expression of MDR1 and BCRP genes / Acompanhamento molecular de pacientes com leucemia mielóide crônica tratados com mesilato de imatinibe e avaliação dos mecanismos de resistência ao tratamento: mutação do gene BCR-ABL e expressão dos genes MDR1 e BCRP
Chronic myeloid leukemia is characterized by t(9;22) translocation. The chimeric gene BCR-ABL encodes a p210BCRABL protein with constitutive tyrosine kinase activity which is directly related to CML pathogenesis. The imatinib mesylate, a tyrosine kinase inhibitor, is the first-choice treatment for patients in chronic phase but some patients show primary resi
Publicado em: 2009
-
12. bcr-abl regulation of TRAIL, OSM, FAIM and NIPA expression. / Controle da expressão de TRAIL, OSM, FAIM e NIPA pelo oncogene bcr-abl.
A leucemia mielóide crônica (LMC) é uma doença mieloproliferativa e sua patogênese está associada à expressão de um neogene, bcr-abl, que codifica uma proteína tirosina quinase Bcr-Abl. Esse trabalho tem como objetivos o estudo dos mecanismos envolvidos na resistência à morte das células Bcr-Abl positivas e a identificação de alterações gêni
Publicado em: 2008